Saniona AB (publ)'s latest marketcap:
As of 06/30/2025, Saniona AB (publ)'s market capitalization has reached $149.18 M. According to our data, Saniona AB (publ) is the 21929th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | $149.18 M |
| Revenue (ttm) | $35.6 M |
| Net Income (ttm) | $22.82 M |
| Shares Out | 136.09 M |
| EPS (ttm) | $0.2 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/28/2025 |
Saniona AB (publ)'s yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 06/30/2025 | kr149.18 M | 56.73% | 21929 |
| 12/30/2024 | kr904.76 M | 251.84% | 24661 |
| 12/29/2023 | kr257.15 M | 34.48% | 32283 |
| 12/30/2022 | kr191.21 M | -65.37% | 33141 |
| 12/30/2021 | kr552.11 M | -57.03% | 26361 |
| 12/30/2020 | kr1.28 B | 75.96% | 18096 |
| 12/30/2019 | kr730.2 M | -2.17% | 19450 |
| 12/28/2018 | kr746.38 M | 11.72% | 18157 |
| 12/29/2017 | kr668.11 M | -21.81% | 19054 |
| 12/30/2016 | kr854.5 M | 153.09% | 16240 |
Company Profile
About Saniona AB (publ)
Saniona AB (publ) is a clinical-stage biopharmaceutical company focused on researching, developing, and commercializing treatments for rare diseases. Headquartered in Glostrup, Denmark, the company operates in Sweden, Germany, Denmark, the United Kingdom, and Mexico.
Key Products & Pipeline
- Tesofensine: A monoamine reuptake inhibitor in Phase 3 clinical trials for obesity treatment.
- Tesomet: An oral investigational therapy in Phase 2b trials for hypothalamic obesity and Prader-Willi syndrome.
- SAN711: A GABAA α3 modulator for absence seizures, completed Phase 1 trials.
- SAN903: A novel calcium-activated potassium ion channel inhibitor for inflammatory bowel disease, in preclinical development.
- SAN2219: A GABAA α2/α3/α5 modulator for acute repetitive seizures, in preclinical stage.
- SAN2355: Targeting refractory focal onset seizures.
- SAN2465: For major depressive disorder.
- Additional programs for epilepsy, Alzheimer’s, schizophrenia, and migraine.
Strategic Collaborations
- Partnership with Boehringer Ingelheim for therapeutic development.
- License agreement with Productos Medix for tesofensine and Tesomet.
- Research collaboration with Cephagenix ApS for migraine treatments.
- Collaboration with AstronauTx for Alzheimer’s disease therapeutics.
Founded in 2011, Saniona AB (publ) continues to advance innovative treatments for unmet medical needs.
Frequently Asked Questions
-
What is Saniona AB (publ)'s (STO-SANION) current market cap?As of 06/30/2025, Saniona AB (publ) (including the parent company, if applicable) has an estimated market capitalization of $149.18 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Saniona AB (publ) (STO-SANION) rank globally by market cap?Saniona AB (publ) global market capitalization ranking is approximately 21929 as of 06/30/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.